FN2 Earnings Intelligence

Novo Nordisk A/S (NVO) earnings history

Novo Nordisk A/S (NVO) quarterly earnings scorecards, market reactions, transcript intelligence, and historical context.

NVO FY2026 Q3 · Calendar Q4 2026

Novo Nordisk A/S

Q3 analysis points to ongoing GLP-1 volume growth—especially Wegovy pill uptake—as a near-term growth support, while price erosion, loss of exclusivity and payer pressure temper confidence in durability.

EPS surprise—
Market move+6.4%

Get the NVO recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.